{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:09:15Z","timestamp":1762999755958,"version":"3.37.3"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1136\/ard-2022-222689","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T17:20:10Z","timestamp":1658769610000},"page":"1585-1593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1530-742X","authenticated-orcid":false,"given":"Woo-Joong","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8108-2412","authenticated-orcid":false,"given":"Seong-Ho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6777-0494","authenticated-orcid":false,"given":"Ji Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-5125","authenticated-orcid":false,"given":"Jung Soo","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-6056","authenticated-orcid":false,"given":"Jin-Won","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2074-1733","authenticated-orcid":false,"given":"Sang Tae","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-222689_bib1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/annrheumdis-2020-218946","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"80","author":"Akiyama","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222689_bib2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.42030","article-title":"SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis","volume":"74","author":"Conway","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222689_bib3","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.immuni.2021.07.017","article-title":"Accelerated COVID-19 vaccine development: milestones, lessons, and prospects","volume":"54","author":"Bok","year":"2021","journal-title":"Immunity"},{"key":"10.1136\/ard-2022-222689_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamainternmed.2021.7024","article-title":"Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US","volume":"182","author":"Sun","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1136\/ard-2022-222689_bib5","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1136\/ard-2022-222689_bib6","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222689_bib7","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1056\/NEJMoa2115926","article-title":"Protection against Covid-19 by BNT162b2 booster across age groups","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med Overseas Ed"},{"key":"10.1136\/ard-2022-222689_bib8","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"The Lancet"},{"key":"10.1136\/ard-2022-222689_bib9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med Overseas Ed"},{"key":"10.1136\/ard-2022-222689_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-222006","article-title":"EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update","author":"Landew\u00e9","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222689_bib11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.15585\/mmwr.mm7106a4","article-title":"Genomic surveillance for SARS-CoV-2 variants: predominance of the delta (B.1.617.2) and omicron (B.1.1.529) variants \u2014 United States, June 2021\u2013January 2022","volume":"71","author":"Lambrou","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1136\/ard-2022-222689_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"10.1136\/ard-2022-222689_bib13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1136\/ard-2022-222689_bib14","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of convalescent and vaccine serum against SARS-CoV-2 omicron","volume":"602","author":"Carre\u00f1o","year":"2022","journal-title":"Nature"},{"key":"10.1136\/ard-2022-222689_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"10.1136\/ard-2022-222689_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"10.1136\/ard-2022-222689_bib17","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"10.1136\/ard-2022-222689_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"10.1136\/ard-2022-222689_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1136\/ard-2022-222689_bib20","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41591-022-01700-x","article-title":"Ancestral SARS-CoV-2-specific T cells cross-recognize the omicron variant","volume":"28","author":"Gao","year":"2022","journal-title":"Nat Med"},{"key":"10.1136\/ard-2022-222689_bib21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-222689_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-Based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"10.1136\/ard-2022-222689_bib23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41591-022-01715-4","article-title":"Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern","volume":"28","author":"Wratil","year":"2022","journal-title":"Nat Med"},{"key":"10.1136\/ard-2022-222689_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-021-01676-0","article-title":"mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 omicron variant","volume":"28","author":"Gruell","year":"2022","journal-title":"Nat Med"},{"key":"10.1136\/ard-2022-222689_bib25","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","article-title":"Humoral immune response to SARS-CoV-2 in Iceland","volume":"383","author":"Gudbjartsson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222689_bib26","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/annrheumdis-2021-221554","article-title":"Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease","volume":"81","author":"Simon","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222689_bib27","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMc2102051","article-title":"Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine","volume":"384","author":"Bradley","year":"2021","journal-title":"N Engl J Med Overseas Ed"},{"key":"10.1136\/ard-2022-222689_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150175","article-title":"Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients","volume":"131","author":"Sattler","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1136\/ard-2022-222689_bib29","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1093\/cid\/ciab555","article-title":"Humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 variants and human coronaviruses after single BNT162b2 vaccination","volume":"73","author":"Stankov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1136\/ard-2022-222689_bib30","article-title":"The impact of prior infection and age on antibody persistence after severe acute respiratory syndrome coronavirus 2 messenger","volume":"384","author":"Fraley","year":"2021","journal-title":"RNA vaccine"},{"key":"10.1136\/ard-2022-222689_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29404-3","article-title":"High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a delta variant surge","volume":"13","author":"Ujjainiya","year":"2022","journal-title":"Nat Commun"},{"key":"10.1136\/ard-2022-222689_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02438-20","article-title":"A new SARS-CoV-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection","volume":"59","author":"Taylor","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1136\/ard-2022-222689_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2021.114228","article-title":"Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2","volume":"297","author":"Mari\u00ebn","year":"2021","journal-title":"J Virol Methods"},{"key":"10.1136\/ard-2022-222689_bib34","article-title":"Clinical performance of a standardized SARS-CoV-2 interferon-\u03b3 release assay for simple detection of T-cell responses after infection or vaccination","author":"Fern\u00e1ndez-Gonz\u00e1lez","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1136\/ard-2022-222689_bib35","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.cmi.2021.09.006","article-title":"The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273","volume":"28","author":"Markewitz","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1136\/ard-2022-222689_bib36","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1136\/ard-2022-222689_bib37","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-222689_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102927","article-title":"Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis","volume":"21","author":"Jena","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2022-222689_bib39","doi-asserted-by":"crossref","first-page":"226","DOI":"10.7326\/M21-3480","article-title":"Neutralization of SARS-CoV-2 variants in transplant recipients after two and three doses of mRNA-1273 vaccine: secondary analysis of a randomized trial","volume":"175","author":"Kumar","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-222689_bib40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.11820921","article-title":"Neutralization of SARS-CoV-2 variants of concern in kidney transplant recipients after standard COVID-19 vaccination","volume":"17","author":"Benning","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1136\/ard-2022-222689_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.0446","article-title":"Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients","volume":"8","author":"Obeid","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1136\/ard-2022-222689_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl6141","article-title":"Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients","volume":"14","author":"Charmetant","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1136\/ard-2022-222689_bib43","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cell.2022.01.027","article-title":"Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals","volume":"185","author":"Lederer","year":"2022","journal-title":"Cell"},{"key":"10.1136\/ard-2022-222689_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1136\/ard-2022-222689_bib45","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222689_bib46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/annrheumdis-2021-222045","article-title":"Efficacy of COVID-19 vaccines in patients taking immunosuppressants","volume":"81","author":"Shen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222689_bib47","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMsb2104756","article-title":"SARS-CoV-2 variants in patients with immunosuppression","volume":"385","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222689_bib48","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jamacardio.2018.1042","article-title":"Association of neutrophil-to-lymphocyte ratio with mortality and cardiovascular disease in the Jackson heart study and modification by the Duffy antigen variant","volume":"3","author":"Kim","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1136\/ard-2022-222689_bib49","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222689_bib50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724183999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724183999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-222689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:00:25Z","timestamp":1737248425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724183999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0003496724183999"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-222689","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-222689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}